F-15599
Based on 2 publication(s) in Google Scholar
F-15599 is a highly selective G-protein biased 5-HT1A receptor agonist, with Ki of 3.4 nM.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 635323-95-4
- Formula: C19H21ClF2N4O
- Molecular Weight:394.85
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) F-15599
MoreAll 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT1A Receptor |
5-HT1A Receptor 3.4 nM (Ki) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 635323-95-4
-
Appearance Solid
-
Molecular Weight 394.85
-
Formula C19H21ClF2N4O
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(F)C(Cl)=C1)N2CCC(CNCC3=NC=C(C)C=N3)(F)CC2
-
Synonyms
NLX-101
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Mol Pharmacol
2023 Nov;104(5):230-238. PMID: 37567783 -
Pharmacol Biochem Behav
Prevention of MK-801-induced amnestic effect with combined activation of 5-HT1A and muscarinic receptors in mice. [Abstract]2024 May:238:173749. PMID: 38462045
Solvent & Solubility
DMSO : 250 mg/mL (633.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (5.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.17 mg/mL (5.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Briefly, in this paradigm, male rats are housed individually in large observation cages (80 × 55 × 50 cm) with an oviduct-ligated female to avoid social isolation and allow sexual behaviour, thereby facilitating territorial behaviour. After 1 week, the baseline level of offensive aggressive behaviour is tested on 3 consecutive days during maximally a 10-min confrontation with an unfamiliar male conspecific (WTG rats). The female partner of the experimental rat is removed from the home observation cage approximately 60 min prior to the start of this social provocation test. Naive male WTG rats, socially housed in groups of 3 in transparent makrolon type IV cages, are used as conspecific intruder animals (average weight 372 ± 9.5 g and 3.5-4 months old). During the first 3 tests, the intruder is removed immediately after the first full attack from the resident and the attack latency time (ALT) is noted. Experimental groups are balanced on the basis of the ALT and the level of offensive behaviour performed during the fourth baseline test (day 4), during which the full range of behaviours is recorded and analysed. Only animals that attacked (i.e. ALT <600 s) are included in the experimental groups. Non-attacking individuals (11 out of 144) are excluded from this study. On the next day (day 5), vehicle (sterile Ultra Pure water, n = 19 and n = 20) or either F15599 (0.0625, 0.125, 0.25, 0.5 and 1.0 mg/kg, IP, experiment 1, n = 45) or F13714 (0.003, 0.006, 0.012, 0.025, 0.062, 0.125, 0.250, IP, experiment 2, n = 50) is administered 30 min before the 10 min confrontation with a drug-free unfamiliar intruder conspecific and their behaviour is recorded again. In addition, in experiment 3, animals are tested 30 min after treatment with either vehicle/vehicle (UP), vehicle/F15599 (0.1 mg/kg) or F13714, WAY-100635 (0.3 mg/kg)/vehicle or WAY100635 (0.3 mg/kg)/ F15599 (0.1 mg/kg) or F13714. Each treatment group consists of 6-8 subjects (n = 41 animals total).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Meadows SM, et al. Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. Exp Neurol. 2017 Jun;292:168-178. [Content Brief]
[2]. de Boer SF, et al. Anti-aggressive effects of the selective high-efficacy 'biased' 5-HT?A receptor agonists F15599 and F13714 in male WTG rats. Psychopharmacology (Berl). 2016 Mar;233(6):937-47. [Content Brief]
[3]. Lladó-Pelfort L, et al. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol. 2010 Aug;160(8):1929-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5326 mL | 12.6630 mL | 25.3261 mL | 63.3152 mL |
| 5 mM | 0.5065 mL | 2.5326 mL | 5.0652 mL | 12.6630 mL | |
| 10 mM | 0.2533 mL | 1.2663 mL | 2.5326 mL | 6.3315 mL | |
| 15 mM | 0.1688 mL | 0.8442 mL | 1.6884 mL | 4.2210 mL | |
| 20 mM | 0.1266 mL | 0.6332 mL | 1.2663 mL | 3.1658 mL | |
| 25 mM | 0.1013 mL | 0.5065 mL | 1.0130 mL | 2.5326 mL | |
| 30 mM | 0.0844 mL | 0.4221 mL | 0.8442 mL | 2.1105 mL | |
| 40 mM | 0.0633 mL | 0.3166 mL | 0.6332 mL | 1.5829 mL | |
| 50 mM | 0.0507 mL | 0.2533 mL | 0.5065 mL | 1.2663 mL | |
| 60 mM | 0.0422 mL | 0.2111 mL | 0.4221 mL | 1.0553 mL | |
| 80 mM | 0.0317 mL | 0.1583 mL | 0.3166 mL | 0.7914 mL | |
| 100 mM | 0.0253 mL | 0.1266 mL | 0.2533 mL | 0.6332 mL |